We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Prospects look somewhat grim for the life sciences industry in the UK, regardless of whether the country decides to completely divorce itself from the EU or do a “soft exit,” a think tank says. Read More
Syntese has received a Form 483 after an inspection revealed sanitation, quality and laboratory control issues at the Denmark-based API maker. Read More
FDA reviewers expressed strong concerns over the possibility of liver damage related to solithromycin treatment ahead of an advisory committee meeting Friday on whether the drug should be approved as an antibiotic for community-acquired bacterial pneumonia. Read More
A pharmaceutical company in Beijing has received a warning letter from the FDA after barring investigators from the facility as well as falsifying and backdating records. Read More
The formal process for disputing a patent before the U.S. Patent and Trademark Office skirts statutory requirements and provides drugmakers with an unfair proceeding that skews outcomes, industry said. Read More
A federal judge in New Jersey has ruled that Merck’s patent infringement lawsuit against generic drug manufacturer Fresenius Kabi can proceed. Read More